Lantis Laser with Optical Coherence Tomography (OCT) is in good company with its exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory and LightLab Imaging. OCT creates a noninvasive technique for imaging subsurface tissue structure with micrometer-scale resolution.
OCT Imaging was the conference topic on Friday, March 23, 2007,during the 85th General Session of the International Association for Dental Research. ” J. Chung et al. and J. Zhang et al., of the University of California-Irvine, presented their work on “3D Imaging of Oral Carcinogenesis with Optical Coherence Tomography” and OCT technology played a prominent role in the earliest possible detection of oral cancer.
The researchers describe Three-dimensional Optical Coherence Tomography (3-D OCT) and Optical Doppler Tomography (ODT), which show surface and subsurface tissues at near-microscopic levels of resolution, with the potential for replacing conventional surgical biopsy and histopathology techniques. Combined with polarimetry, accurate delineation of lesion margins becomes possible. Scanning is painless and non-invasive, lasting less than one minute with a pen-sized hand-held probe. This device’s resolution or diagnostic capability may dictate its primary use as an indicator of the need for biopsy. Later, this modality may progressively reduce the need for biopsy, define surgical margins, and permit the direct evaluation of cancer treatments. In combination with OCT-visible molecular probes, this modality will greatly advance cancer diagnostics.
Oral cancer is diagnosed in more than 30,000 individuals in the US annually, claiming 10,000 lives each year. Early detection remains the best way to ensure patient survival and quality of life. During the 85th General Session of the International Association for Dental Research, scientists from the University of California- Irvine presented two novel, non-invasive, ultra-fast imaging approaches to oral cancer detection, diagnostic screening, and mapping.
More than 2/3 of all oral cancer cases documented by the National Cancer Institute are diagnosed at an advanced stage. The five-year survival rate is 75% for those with localized disease at diagnosis, but only 16% for those with cancer metastasis. Earlier detection of oral lesions would greatly improve the prognosis of these patients. Accurate delineation of lesion margins would ensure effective removal of all the tissue that presents a threat to the patient’s long-term health. Two basic facts indicate that early detection of oral malignancy should be possible to a far greater extent than is currently seen:
(1) Accounting for 96% of all oral cancers, squamous cell carcinoma is often preceded by lesions on the oral mucosa. Malignant transformation, which is quite unpredictable, occurs in 1-90% of lesions over five years. Thus, oral cancer is often preceded by lesions which are visible to the naked eye prior to transformation. A non-invasive diagnostic modality would permit regular monitoring of these lesions, detection of lesion transformation, and the identification of treatment needs at a very early, relatively harmless stage.
(2) High-risk populations are clearly defined: tobacco use, alcohol abuse, urban environment, specific ethnicities, poor diet, and frequent exposure to sunlight. A fast, mobile, relatively inexpensive and non-invasive diagnostic modality would permit the early detection and monitoring of oral lesions.
Lantis Laser with Optical Coherence Tomography (OCT) has the potential to play a dominant role in detecting oral cancer and saving lives. Specifically OCT enables the dentist to make earlier and more accurate diagnosis of oral diseases such as decay and periodontal diseases. Early detection enables non- or minimally invasive techniques to be employed to arrest, and even reverse oral diseases.
Source: Lantis Laser Inc. and Clinical Oncology Weekly
Contact: Lantis Laser Inc.
Stan Baron,President and CEO
11 Stonebridge Court
Denville, NJ 07834
Tel: (203) 300-7622
Forward-Looking Statements: Certain statements in this press release, including statements regarding the anticipated development and expansion of Lantis’ business, and the intent, belief or current expectations of Lantis, its directors or its officers, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statement
Disclosure: Pentony Enterprises LLC was compensated $15,000 directly from the company and 55,000 free trading shares from a non controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises holds no thousand shares.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .